# TLX earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/TLX) · [Earnings tab](https://www.lopjlb.com/stock/TLX?tab=earnings) Updated: 2026-08-21T07:43:51 Quarters analyzed: 8 ## Cross-quarter narrative Across 8 calls for TLX, management tone moved from +0.60 (2023 Q3) to +0.60 (2026 Q2). Latest guidance stance: maintained. Latest desk line: Telix reported 22% revenue growth to $477M, improved margins and EBITDA, maintained FY2026 revenue guidance, and highlighted progress on Pixclara, Zircaix, BiPASS and multiple therapeutic programs. ## Latest CallCard · Q2 Telix reported 22% revenue growth to $477M, improved margins and EBITDA, maintained FY2026 revenue guidance, and highlighted progress on Pixclara, Zircaix, BiPASS and multiple therapeutic programs. **Guidance:** maintained — Full‑year revenue guidance of $950‑$970 million is maintained, with expectation to land at the upper end. **Tone:** mgmt 0.6 · Q&A pressure 0.4 · divergence 0.2 Prepared remarks emphasized strong commercial execution, margin expansion and pipeline progress, projecting confidence in hitting the upper end of guidance. ### Demand visibility Strong demand for PSMA imaging portfolio, especially Gozellix and Illuccix. Demand was strong from day 1, adoption reinforces the two‑product strategy and supports >20% YoY growth in Precision Medicine. ### Margins / costs Margins improved across the business. Precision Medicine gross margin rose to 65% (+1% YoY) and consolidated gross margin to 55% (+2% YoY); EBITDA grew 146% YoY. ### Capital allocation Reinvesting earnings into R&D and capex while maintaining cash strength. R&D spending was 26% of revenue; capex ongoing at Seneffe, Yokohama, RLS and new translational research site in Melbourne. ### Milestones - **Pixclara US submission** [on_track]: PDUFA date set for September 11; European submission completed. - **Zircaix resubmission** [on_track]: Corrected CRL received; resubmission expected within next 1‑2 months. - **BiPASS enrollment** [on_track]: Trial recruited full sample in 5 months, indicating strong physician interest. - **ProstACT Global Part 2 IND amendment** [on_track]: FDA safety data review completed; IND amendment filing planned after upcoming meeting. - **TLX597 Phase II studies** [on_track]: OPTIMAL‑PSMA enrollment complete; dosing started in OPTIMAL‑e. - **TLX090 Phase I study** [on_track]: Dosing patients for bone‑pain palliation indication. - **Melbourne translational research site** [delivered]: New integrated R&D and patient‑care facility opened. - **RLS manufacturing integration** [on_track]: CapEx expanding clean‑room capacity, cyclotrons and licensing for lutetium therapeutics. ### Fears / risks - **Regulatory risk**: Timing of Zircaix resubmission and Pixlumi decision remain uncertain and could affect launch timelines. - **Market competition**: New TruVu product may affect PSMA market dynamics, though management sees limited impact. - **Supply chain complexity**: Radiopharma products require just‑in‑time manufacturing; any disruption could delay patient dosing. - **Clinical trial enrollment**: BiPASS and ProstACT Global enrollment rates and statistical powering adjustments introduce execution risk. - **Cash burn**: R&D spending at 26% of revenue and ongoing capex could pressure cash balances. - **Guidance conservatism**: Guidance does not reflect upside from unapproved products, leaving upside potential unquantified. - **Regulatory feedback**: Potential clock‑stops or additional queries in Pixlumi review could extend the 18‑month timeline. - **Geographic rollout**: NDA submissions in China and Japan are pending regulatory review, adding uncertainty to international revenue. ### Key quotes > “We are a pure-play radiopharmaceutical firm, and our strength is based on five core pillars of activity.” > “The launch of Gozellix has been very successful. Demand was strong from day 1, and the adoption we've seen reinforces that our two-product strategy is delivering exactly what we've intended.” > “EBITDA improved 146% year-on-year to $52 million, and net profit after tax was up to $38 million, reflecting strong business performance and continued control of operating expenditure.” > “That would be a reasonable assumption.” — Christian Behrenbruch ## Quarter one-liners - **2026 Q2:** Telix reported 22% revenue growth to $477M, improved margins and EBITDA, maintained FY2026 revenue guidance, and highlighted progress on Pixclara, Zircaix, BiPASS and multiple therapeutic programs. - **2025 Q4:** Telix posted 56% revenue growth to $804M, highlighted strong Precision Medicine cash generation and Gozellix launch, but faces European reimbursement delays and pending FDA resubmissions for Pixclara and Zircaix. - **2025 Q2:** — - **2025 Q1:** Telix reported 63% revenue growth, reaffirmed full‑year guidance and highlighted manufacturing investments, new product launches and an Al‑F chemistry program while downplaying pricing pressure concerns. - **2024 Q4:** Telix reported a 56% revenue jump in FY2024 driven by Illuccix, announced three US product launches for 2025, expanded manufacturing in Europe, and raised FY2025 guidance above $1 billion, while noting regulatory and integration risks. - **2024 Q2:** — - **2023 Q4:** Telix achieved 214% revenue growth to $512M in FY2023, first profit and positive cash flow, advancing two diagnostic launches (Pixclara, Zircaix) and therapeutic pipeline (ProstACT GLOBAL, TLX592). - **2023 Q3:** Telix reported fourth straight quarter of positive cash flow, double‑digit Illuccix growth and progress on multiple pipeline assets, while flagging regulatory timing and reimbursement uncertainties. ## Theme arcs - **Management tone** (stable): Δ mgmt=+0.00 ## Fear persistence - **regulatory/reimbursement** [resolved]: 2023 Q3 - **competitive** [resolved]: 2023 Q3 - **operational** [resolved]: 2023 Q3 - **clinical** [resolved]: 2023 Q3 - **financial** [resolved]: 2023 Q3 - **regulatory timing** [resolved]: 2023 Q3 - **dosing strategy** [resolved]: 2023 Q3 - **strategic integration** [resolved]: 2023 Q3 - **regulatory approval risk** [resolved]: 2023 Q4 - **clinical trial risk** [recurring]: 2023 Q4, 2025 Q4 ## Guidance path 2023 Q3:maintained → 2023 Q4:vague → 2024 Q2:vague → 2024 Q4:raised → 2025 Q1:maintained → 2025 Q2:vague → 2025 Q4:maintained → 2026 Q2:maintained --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/TLX`